Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Successful Treatment of Corticosteroid-Refractory Hypereosinophilia With Reslizumab.

Coffey K, Fajt ML, Acho M, Gladwin M, Petrov AA.

J Investig Allergol Clin Immunol. 2019 Jun;29(3):241-242. doi: 10.18176/jiaci.0366. No abstract available.

2.

Successful Lung Transplantation in a Patient with Chronic Granulomatous Disease.

Xie M, Lee J, Crespo M, Fajt ML, Shigemura N, Pilewski JM, Petrov AA.

J Clin Immunol. 2019 May;39(4):347-349. doi: 10.1007/s10875-019-00623-6. Epub 2019 Apr 23. No abstract available.

PMID:
31016643
3.

Extracellular DNA, Neutrophil Extracellular Traps, and Inflammasome Activation in Severe Asthma.

Lachowicz-Scroggins ME, Dunican EM, Charbit AR, Raymond W, Looney MR, Peters MC, Gordon ED, Woodruff PG, Lefrançais E, Phillips BR, Mauger DT, Comhair SA, Erzurum SC, Johansson MW, Jarjour NN, Coverstone AM, Castro M, Hastie AT, Bleecker ER, Fajt ML, Wenzel SE, Israel E, Levy BD, Fahy JV.

Am J Respir Crit Care Med. 2019 May 1;199(9):1076-1085. doi: 10.1164/rccm.201810-1869OC.

PMID:
30888839
4.

Co-existence of vocal cord dysfunction with pulmonary conditions other than asthma: A case series.

Fajt ML, Birnie KM, Trejo Bittar HE, Petrov AA.

Respir Med Case Rep. 2018 Aug 3;25:104-108. doi: 10.1016/j.rmcr.2018.08.001. eCollection 2018.

5.

Effects of endogenous sex hormones on lung function and symptom control in adolescents with asthma.

DeBoer MD, Phillips BR, Mauger DT, Zein J, Erzurum SC, Fitzpatrick AM, Gaston BM, Myers R, Ross KR, Chmiel J, Lee MJ, Fahy JV, Peters M, Ly NP, Wenzel SE, Fajt ML, Holguin F, Moore WC, Peters SP, Meyers D, Bleecker ER, Castro M, Coverstone AM, Bacharier LB, Jarjour NN, Sorkness RL, Ramratnam S, Irani AM, Israel E, Levy B, Phipatanakul W, Gaffin JM, Gerald Teague W.

BMC Pulm Med. 2018 Apr 10;18(1):58. doi: 10.1186/s12890-018-0612-x.

6.

ALX receptor ligands define a biochemical endotype for severe asthma.

Ricklefs I, Barkas I, Duvall MG, Cernadas M, Grossman NL, Israel E, Bleecker ER, Castro M, Erzurum SC, Fahy JV, Gaston BM, Denlinger LC, Mauger DT, Wenzel SE, Comhair SA, Coverstone AM, Fajt ML, Hastie AT, Johansson MW, Peters MC, Phillips BR, Levy BD; National Heart Lung and Blood Institute’s Severe Asthma Research Program- Investigators.

JCI Insight. 2018 Mar 22;3(6). pii: 120932. doi: 10.1172/jci.insight.120932. No abstract available.

7.

Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids.

Peters MC, Kerr S, Dunican EM, Woodruff PG, Fajt ML, Levy BD, Israel E, Phillips BR, Mauger DT, Comhair SA, Erzurum SC, Johansson MW, Jarjour NN, Coverstone AM, Castro M, Hastie AT, Bleecker ER, Wenzel SE, Fahy JV; National Heart, Lung and Blood Institute Severe Asthma Research Program 3.

J Allergy Clin Immunol. 2019 Jan;143(1):104-113.e14. doi: 10.1016/j.jaci.2017.12.1009. Epub 2018 Mar 7.

PMID:
29524537
8.

Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age.

Teague WG, Phillips BR, Fahy JV, Wenzel SE, Fitzpatrick AM, Moore WC, Hastie AT, Bleecker ER, Meyers DA, Peters SP, Castro M, Coverstone AM, Bacharier LB, Ly NP, Peters MC, Denlinger LC, Ramratnam S, Sorkness RL, Gaston BM, Erzurum SC, Comhair SAA, Myers RE, Zein J, DeBoer MD, Irani AM, Israel E, Levy B, Cardet JC, Phipatanakul W, Gaffin JM, Holguin F, Fajt ML, Aujla SJ, Mauger DT, Jarjour NN.

J Allergy Clin Immunol Pract. 2018 Mar - Apr;6(2):545-554.e4. doi: 10.1016/j.jaip.2017.05.032. Epub 2017 Aug 31.

9.

Natural killer cell-mediated inflammation resolution is disabled in severe asthma.

Duvall MG, Barnig C, Cernadas M, Ricklefs I, Krishnamoorthy N, Grossman NL, Bhakta NR, Fahy JV, Bleecker ER, Castro M, Erzurum SC, Gaston BM, Jarjour NN, Mauger DT, Wenzel SE, Comhair SA, Coverstone AM, Fajt ML, Hastie AT, Johansson MW, Peters MC, Phillips BR, Israel E, Levy BD; National Heart, Lung, and Blood Institute’s Severe Asthma Research Program-3 Investigators.

Sci Immunol. 2017 Mar 10;2(9). pii: eaam5446. doi: 10.1126/sciimmunol.aam5446.

10.

ALX receptor ligands define a biochemical endotype for severe asthma.

Ricklefs I, Barkas I, Duvall MG, Cernadas M, Grossman NL, Israel E, Bleecker ER, Castro M, Erzurum SC, Fahy JV, Gaston BM, Denlinger LC, Mauger DT, Wenzel SE, Comhair SA, Coverstone AM, Fajt ML, Hastie AT, Johansson MW, Peters MC, Phillips BR, Levy BD; National Heart Lung and Blood Institute’s Severe Asthma Research Program-3 Investigators.

JCI Insight. 2017 Jul 20;2(14). pii: 93534. doi: 10.1172/jci.insight.93534. eCollection 2017 Jul 20. Erratum in: JCI Insight. 2018 Mar 22;3(6):.

11.

A 10-year experience of a novel and safe modified environmental rush immunotherapy protocol.

Fajt ML, Rosenberg SL, Yecies E, Traister RS, Petrov AA.

Allergy Asthma Proc. 2017 Jul 1;38(4):309-316. doi: 10.2500/aap.2017.38.4053.

PMID:
28668111
12.

A Novel Pretreatment Regimen for Breakthrough Radiocontrast Media Anaphylaxis in Cardiac Patients.

Montandon SV, Petrov AA, Fajt ML.

Crit Pathw Cardiol. 2016 Dec;15(4):161-164.

PMID:
27846008
13.

Development of New Therapies for Severe Asthma.

Fajt ML, Wenzel SE.

Allergy Asthma Immunol Res. 2017 Jan;9(1):3-14. doi: 10.4168/aair.2017.9.1.3. Review.

14.

The morbidity and cost of vocal cord dysfunction misdiagnosed as asthma.

Traister RS, Fajt ML, Petrov AA.

Allergy Asthma Proc. 2016 Mar-Apr;37(2):25-31. doi: 10.2500/aap.2016.37.3936.

PMID:
26932166
15.

Reply: Secreted Brain-Derived Neurotrophic Factor and Asthma Severity.

Watanabe T, Fajt ML, Wenzel SE; All The Authors.

Am J Respir Cell Mol Biol. 2016 Feb;54(2):297-8. doi: 10.1165/rcmb.2015-0285LE. No abstract available.

16.

Blood eosinophils: the Holy Grail for asthma phenotyping?

Fajt ML.

Ann Allergy Asthma Immunol. 2016 Feb;116(2):90-1. doi: 10.1016/j.anai.2015.12.004. No abstract available.

PMID:
26815702
17.

A Safe and Novel Desensitization Protocol with Ferric Carboxymaltose to Treat Iron Deficiency Anemia.

Montandon SV, Fajt ML, Petrov AA.

Curr Drug Saf. 2016;11(2):145-8.

PMID:
26647917
18.

Brain-Derived Neurotrophic Factor Expression in Asthma. Association with Severity and Type 2 Inflammatory Processes.

Watanabe T, Fajt ML, Trudeau JB, Voraphani N, Hu H, Zhou X, Holguin F, Wenzel SE.

Am J Respir Cell Mol Biol. 2015 Dec;53(6):844-52. doi: 10.1165/rcmb.2015-0015OC.

19.

Angiotensin receptor blocker-induced visceral angioedema.

Thalanayar MP, Fajt ML, Birnie KM, Ghobrial II, Petrov AA.

J Investig Allergol Clin Immunol. 2015;25(1):63-4. No abstract available.

20.

Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care.

Fajt ML, Wenzel SE.

J Allergy Clin Immunol. 2015 Feb;135(2):299-310; quiz 311. doi: 10.1016/j.jaci.2014.12.1871. Review.

PMID:
25662302
21.

Desensitization protocol for rituximab-induced serum sickness.

Fajt ML, Petrov AA.

Curr Drug Saf. 2014;9(3):240-2.

PMID:
24861993
22.

Biologic therapy in asthma: entering the new age of personalized medicine.

Fajt ML, Wenzel SE.

J Asthma. 2014 Sep;51(7):669-76. doi: 10.3109/02770903.2014.910221. Epub 2014 May 13. Review.

PMID:
24712500
23.

A novel scoring system to distinguish vocal cord dysfunction from asthma.

Traister RS, Fajt ML, Landsittel D, Petrov AA.

J Allergy Clin Immunol Pract. 2014 Jan-Feb;2(1):65-9. doi: 10.1016/j.jaip.2013.09.002. Epub 2013 Nov 2.

PMID:
24565771
24.

Mast cells, their subtypes, and relation to asthma phenotypes.

Fajt ML, Wenzel SE.

Ann Am Thorac Soc. 2013 Dec;10 Suppl:S158-64. doi: 10.1513/AnnalsATS.201303-064AW.

PMID:
24313767
25.

A retrospective analysis comparing subjects with isolated and coexistent vocal cord dysfunction and asthma.

Traister RS, Fajt ML, Whitman-Purves E, Anderson WC, Petrov AA.

Allergy Asthma Proc. 2013 Jul-Aug;34(4):349-55. doi: 10.2500/aap.2013.34.3673.

PMID:
23883599
26.

Prostaglandin D₂ pathway upregulation: relation to asthma severity, control, and TH2 inflammation.

Fajt ML, Gelhaus SL, Freeman B, Uvalle CE, Trudeau JB, Holguin F, Wenzel SE.

J Allergy Clin Immunol. 2013 Jun;131(6):1504-12. doi: 10.1016/j.jaci.2013.01.035. Epub 2013 Mar 16.

27.

Successful treatment of exercise-induced anaphylaxis with omalizumab.

Bray SM, Fajt ML, Petrov AA.

Ann Allergy Asthma Immunol. 2012 Oct;109(4):281-2. doi: 10.1016/j.anai.2012.07.021. Epub 2012 Aug 15. No abstract available.

PMID:
23010237
28.

Outpatient aspirin desensitization for patients with aspirin hypersensitivity and cardiac disease.

Fajt ML, Petrov AA.

Crit Pathw Cardiol. 2011 Mar;10(1):17-21. doi: 10.1097/HPC.0b013e318213d5a6.

PMID:
21562370
29.

Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program.

Balzar S, Fajt ML, Comhair SA, Erzurum SC, Bleecker E, Busse WW, Castro M, Gaston B, Israel E, Schwartz LB, Curran-Everett D, Moore CG, Wenzel SE.

Am J Respir Crit Care Med. 2011 Feb 1;183(3):299-309. doi: 10.1164/rccm.201002-0295OC. Epub 2010 Sep 2.

30.

Asthma phenotypes in adults and clinical implications.

Fajt ML, Wenzel SE.

Expert Rev Respir Med. 2009 Dec;3(6):607-25. doi: 10.1586/ers.09.57.

PMID:
20477351

Supplemental Content

Support Center